Hereditary sensory and autonomic neuropathy

Related records

Broader conditions (14)

• Disease
• Disease by body system or component
• Disease by etiologic mechanism
• Disease of genetic or genomic mechanism
• Hereditary disease
• Hereditary neurological disease
• Hereditary neuromuscular disease
• Hereditary peripheral neuropathy
• Human disease
• Nervous system disorder
• Neuromuscular disease
• Peripheral nervous system disorder
• Peripheral neuropathy
• Sensory peripheral neuropathy

Narrower conditions (32)

• Cerebellar ataxia with neuropathy and bilateral vestibular areflexia syndrome
• Channelopathy-associated congenital insensitivity to pain, autosomal recessive
• Cold-induced sweating syndrome
• Cold-induced sweating syndrome - hyperthermia spectrum
• Cold-induced sweating syndrome 1
• Cold-induced sweating syndrome 2
• Congenital insensitivity to pain
• Congenital insensitivity to pain syndrome, Marsili type
• Congenital insensitivity to pain with hyperhidrosis
• Congenital insensitivity to pain with severe intellectual disability
• Congenital insensitivity to pain-hypohidrosis syndrome
• Hereditary sensory and autonomic neuropathy type 1
• Hereditary sensory and autonomic neuropathy type 2
• Hereditary sensory and autonomic neuropathy type 4
• Hereditary sensory and autonomic neuropathy type 5
• Hereditary sensory and autonomic neuropathy type 6
• Hereditary sensory and autonomic neuropathy type 7
• Hereditary sensory neuropathy X-linked
• Hereditary sensory neuropathy-deafness-dementia syndrome
• Hereditary spastic paraplegia 49

Trials (175)

• 24VA022; VATCH Alpelisib for TIE2/PIK3CA Pathway VAs
• 9-ING-41 Combined With Retifanlimab, Plus Modified FOLFIRINOX for Patients With Advanced Pancreatic Adenocarcinoma (RiLEY)
• 9-ING-41 in Patients With Advanced Cancers
• A Clinical Study To Investigate The Effectiveness And Safety Of Tanezumab In Treating Pain Associated With Endometriosis
• A Multi-Center Study on the Use of Rho-Kinase Inhibitor to Reduce or Prevent PVR in RRD Eyes at High Risk for PVR
• A Phase 2 Study of RTB101 as COVID-19 Post-Exposure Prophylaxis in Older Adults
• A Phase I Study of BKM120 and Everolimus in Advanced Solid Malignancies
• A Phase I Study of RGT-264 in Subjects With Advanced Solid Tumors
• A Phase I Study, Evaluating the Safety, Pharmacokinetics and Efficacy of PRJ1-3024 in Subjects With Advanced Solid Tumors
• A Phase I/II Study of BGT226 in Adult Patients With Advanced Solid Malignancies Including Patients With Advanced Breast Cancer
• A Phase I/II Study to Evaluate the Safety, Pharmacokinetics and Efficacy of PRJ1-3024 in Subjects with Advanced Solid Tumors
• A Phase Ib/II Study of BYL719 and Cetuximab in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
• A Phase II Study of Single Agent MEK162 in Patients With Advanced Melanoma
• A Phase III Study of BKM120 With Fulvestrant in Patients With HR+,HER2-, AI Treated, Locally Advanced or Metastatic Breast Cancer Who Progressed on or After mTORi
• A Single Arm, Phase Ib/II Trial of Single Agent Pacritinib in Patients With 1q21.3 Amplified Solid Tumors Enriching for Interleukin-1 Receptor-associated Kinase 1 Pathway Activation (PAIR)
• A Study Investigating DNA-damage Response Agents in Molecularly Altered Advanced Cancer
• A Study Investigating the Efficacy and Safety of BGB-45035 Versus Placebo in Adults With Moderate to Severe Active Rheumatoid Arthritis
• A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors
• A Study of AZD2962, an IRAK4 Inhibitor (IRAK4 [a Body Protein] Blocker), in Participants With Haematologic Neoplasms (Blood Cancers)
• A Study of INCB050465 in Combination With Ruxolitinib in Subjects With Myelofibrosis